Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces a collaboration with Seegene USA, Inc.
(“
Seegene USA”), a leading developer of multiplex
molecular assays and automated solutions for U.S. labs. Under the
parties’ collaboration, Seegene USA will distribute and recommend
Microbix’s Quality Assessment Products (“
QAPs™”)
to monitor the workflow accuracy of Seegene Novaplex™ and Allplex™
assays in use across the United States.
Microbix QAPs are available to support PCR-based
(molecular) assays formatted on Copan® FLOQSwabs® and
room-temperature stable, or in liquid vial format that are
refrigerator-temperature stable. Microbix PROCEEDx® brand QAPs are
Research Use Only “RUO” samples, while its REDx® brand QAPs are
In-Vitro Diagnostic “IVD” Controls. Regular use of QAPs helps
ensure the accuracy of laboratory-conducted assays.
With this agreement, Seegene USA will begin
offering Microbix’s QAPs products, alongside its current portfolio
of high multiplex PCR assays that test for infectious disease
pathogens under its Allplex™ and Novaplex™ brands. These assays,
using Seegene proprietary technology, are unique in their ability
to produce high-multiplex results from a single channel in a PCR
reaction. In combination, US labs receive an efficient, low-cost
approach to achieve high-quality syndromic testing for infectious
disease pathogens when compared to currently available options.
Philip Casselli, SVP Business Development,
commented, “Our longstanding relationship with Seegene Canada laid
a strong foundation for this Microbix – Seegene USA relationship.
Our collaboration naturally aligns the two companies to help assure
optimal results for laboratories performing high-multiplex PCR
testing using Seegene Assays. This week we began our training and
comprehensive support of the Seegene USA team.”
“In this partnership, we are again increasing
our IVD presence for the U.S. and further supporting our lab
customers in their mission to better provide quality results for
their patients and institutions,” said Craig Howell, SVP for
Marketing of Seegene USA, Inc. “As well, we believe our ongoing IVD
assay development requires custom control and validation panel
expertise that is met by Microbix’s competencies.”
About Seegene USA, Inc.Seegene
USA Inc. is based in Irvine, CA and is a subsidiary of Seegene Inc.
of Seoul, Republic of Korea. Seegene companies are global leaders
in multiplex molecular diagnostics and offer platforms with
real-time PCR amplification technologies. The Seegene Inc. global
network covers over 85 countries, with subsidiaries in Brazil,
Canada, Germany, Italy, Mexico, the Middle East, and the United
States. Please visit www.seegeneus.com or contact us at
info.seegeneusa@seegene.com for further information.
Novaplex™ Assay PanelsSeegene
Novaplex™ assays are real-time reverse transcriptase polymerase
chain reaction (RT-PCR) tests that maximize test efficiency and
offer excellent performance. These syndromic assays simultaneously
test for multiple targets in short running time with reduced
reagents cost and minimal labor required. Novaplex reagents are for
Research Use Only (RUO) and not for use in diagnostic
procedures.
Allplex™ 2019-nCoVThe Allplex™
2019-nCoV (SARS-CoV-2) Assay is available in the U.S. under an
Emergency Use Authorization “EUA”. Seegene has played a critical
role in offering effective testing solutions that include current
variants to mitigate the spread of rapidly mutating COVID-19
viruses.
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and annualized sales targeting C$ 2.0 million per month.
It makes a wide range of critical ingredients and devices for the
global diagnostics industry, notably antigens for immunoassays and
its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Its antigens drive the antibody tests of approximately
100 diagnostics makers, while QAPs are sold to clinical lab
accreditation organizations, diagnostics companies, and clinical
labs. Microbix QAPs are now available in over 30 countries,
supported by a network of international distributors. Microbix is
ISO 9001 & 13485 accredited, U.S. FDA registered, Australian
TGA registered, Health Canada establishment licensed, and provides
CE marked products.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of Seegene USA
and its assays, Microbix and its QAPs, their relevance, or others’
products or services, business and business results, goals or
outlook, risks associated with financial results and stability,
development projects such as those referenced in its presentations,
regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity or timeliness of delivery),
currency exchange rates, maintaining adequate working capital or
raising new capital on acceptable terms or at all, and other
similar statements about anticipated future events, conditions or
results that are not historical facts. These statements reflect
management’s current estimates, beliefs, intentions, and
expectations; they are not guarantees of future performance.
Microbix cautions that all forward-looking information is
inherently uncertain and actual performance may be affected by many
material factors, some of which are beyond its control.
Accordingly, actual future events, conditions and results may
differ materially from the estimates, beliefs, intentions, and
expectations expressed or implied in the forward-looking
information. All statements are made as of the date of this news
release and represent Microbix’s judgement as of the date of this
new release, and it is under no obligation to update or alter any
forward-looking information.
Please visit https://microbix.com or
www.sedarplus.ca for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
|
Copyright © 2023 Microbix Biosystems Inc. &
Seegene USA, Inc. Microbix®, DxTM™, Kinlytic®, PROCEEDx®, QAPs™,
and REDx® are trademarks of Microbix Biosystems Inc.Seegene®,
Allplex™, and Novaplex™ are trademarks of Seegene Inc. or its
affiliates.Copan® and FLOQSwab® are trademarks of Copan Italia
S.p.A.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024